AU2002324712A1 - A pellet implant system and method of administration - Google Patents

A pellet implant system and method of administration

Info

Publication number
AU2002324712A1
AU2002324712A1 AU2002324712A AU2002324712A AU2002324712A1 AU 2002324712 A1 AU2002324712 A1 AU 2002324712A1 AU 2002324712 A AU2002324712 A AU 2002324712A AU 2002324712 A AU2002324712 A AU 2002324712A AU 2002324712 A1 AU2002324712 A1 AU 2002324712A1
Authority
AU
Australia
Prior art keywords
pharmaceutical
pellet
animal
implant
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002324712A
Inventor
Colin B. Campbell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co LLC
Original Assignee
Pharmacia and Upjohn Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co LLC filed Critical Pharmacia and Upjohn Co LLC
Publication of AU2002324712A1 publication Critical patent/AU2002324712A1/en
Abandoned legal-status Critical Current

Links

Description

A PELLET IMPLANT SYSTEM AND METHOD OF ADMINISTRATION
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a pellet implant system and method which
administers an implantable non-pharmaceutical pellet implant subcutaneously along with a pharmaceutical pellet implant in a single combined procedure.
2. Description of the Related Art
Implants for delivering doses of pharmaceutical agents to animals and humans are widely used and well known in the art. Classes of pharmaceutical agents for which implants are widely used include, among others, time delayed pharmaceuticals, nutritional supplements, growth stimulants, contraceptive steroids, hormones,
antibodies, antigens, biologies, vaccines, prostaglandins, narcotic antagonists, anti- arrhythmics, biocides for flea and parasite control in humans, horses, and domestic animals such as dogs and cats. Implants are commonly used in farm animals in the areas of animal health and production enhancement. For example, growth stimulants administered as implants are commonly used to enhance growth and improve carcass quality of animals which are raised for slaughtering, such as cattle, swine, sheep,
turkeys, chickens, and the like. Pharmaceutical implants are generally prepared as small solid pellets and are injected under the skin of the animal. Implantable identification devices, which can be implanted under the skin or
an animal or human used for identification of individual animals or humans, are
known in the art. One example of such a device is electronic integrated circuit
microchips. The microchip is implanted under the skin of an animal and carries coded
information which can be used, for example, to identify an animal when the chip is
scanned. Microchips are widely used for the identification of livestock, companion animals, fisheries, and wild animals. The microchips may also contain information
such as the animal's medical history, or relevant commercial information. The
outbreaks of foot and mouth disease and mad cow disease (bovine spongiform
encephalopathy) make identification of carrier animals extremely important. By
having an identification device in the animal the veterinarian would know precisely what treatment regimen the animal will have been given.
Microchips are also implanted under the skin of humans. Microchips could contain identifying information which may be useful in detecting abducted children or run-away children. Microchips could also contain vaccination and medical information which could be useful to school personnel. For adults a microchip could contain information that alerts a doctor that the person is epileptic or diabetic.
Microchips and pharmaceutical pellet implants may be administered using similar apparatus and procedure. Generally, pellets or chips are administered by an implanter equipped with a hypodermic needle. The needle is used to puncture the skin of the animal or human. Pellets or chips are forced through the needle and left under the skin as the needle is removed. In the case of farm animals, the pellets or chips are normally implanted under the skin of the ear while an animal is confined in a chute.
Because of the widespread use of implantable identification devices and pharmaceutical implants, it is quite common that one individual animal is implanted
with both an identification device implant and a pharmaceutical pellet implant, which is currently done through separate injections. Thus, in such a case, two or more
separate punctures have to be made in the skin of an animal.
There are several problems associated with the currently used system and
procedures. First, performing the implanting procedure is relative labor-intensive,
particularly when a large number of animals are involved. A more troubling problem, which his commonly encountered in administering the implants to a large number of
farm animals, is the infection at the puncture site. In the case of farm animals, it is
typically that during one implanting session a large number of animals are implanted
in rapid sequence, with the same needle often used with as many as 100 or more
animals. Moreover, these injections often occur in or near feedlots or other locations
with considerably less than ideal sanitary conditions. It is virtually impossible in such situations to provide a sterile injection site on a single animal or to prevent transfer of infective microbes from one animal to the next on the injecting needle. Further complicating the matter is that other procedures may be occurring at the same time as the implanting operation while the animal is confined, such as branding, veterinary inspections or procedures, or the like, which may further excite the animal and make injecting and disinfecting difficult. It is not unusual to even have manure at the injection site. Since these implantations involve the deliberate making of a puncture wound in the animal's skin, bacteria are introduced into the implant sites, either during the delivery of the implant or thereafter, which may cause an infection at the site. Such infections may and often do result in abscesses, which may reduce the effectiveness of the implant by encapsulation of the implant pellet or by pushing the therapeutic pellet out of the original insertion implant receiving puncture, thereby preventing absorption and transport of the active ingredients. It is estimated that from about 10% to about
15% of feedlot cattle which are implanted in the United States subsequently develop
abscesses.
The above problems are compounded where an animal is administered both an
identification device implant and a pharmaceutical implant through separate skin
punctures and separate injections. Multiple injections not only increase the labor requirement for administering the implants, they inevitably put the animal in a higher
risk for infections.
A variety of techniques are currently employed to reduce the incidence of
infection. Implant manufacturers recommend disinfection of the implanting tool,
pellet magazines and needles, and observation of good sanitation practices during the implantation process. The implantation site may be cleaned or disinfected prior to
injection to help prevent entry of resident bacteria into the implant receiving puncture and the needle, which may be employed to inject dozens of animals, may be disinfected between animals to prevent the transfer of bacteria from one animal to the next. U.S. Patent 5,817,054 (1998 to Grimm) describes an implanter with a disinfectant dispenser that introduce a disinfectant into the skin puncture wound forming the implant area of each receiving animal. U.S. Patent 5,870,098 (1999 to Stevens and Spurlin) describes an antibiotic and pharmaceutical pellet system and method of providing localized sustained antibiotic release as part of a single therapeutic procedure in order to prevent infection at the injection site. While all such measures may serve to increase sanitation and to reduce initial contamination of the implant receiving puncture, they inevitably increase the cost, time, and labor for
administering the implants. Moreover, none of these methods reduce the total number of punctures made in the animal skin, and thus does not reduce the opportunity of
entry of microorganisms into the animal body through the punctures. Further, the
method described in U.S. Patent 5,817,054 and U.S. Patent 5,870,098 requires the introduction of additional chemical agents, which may have undesirable effects on the
animals or on the quality of the animal products.
Accordingly, there is clearly a need for a better system and method of
implanting a plurality of pellets including one identification device pellet to an animal. SUMMARY OF INVENTION
It is an object of the invention to provide a pellet implant system and method
which would reduce the total number of skin punctures required for administering a
plurality of implants that include at least one pharmaceutical pellet implant and at
least one non-pharmaceutical device implant into an animal or human, thus reducing the opportunity of bacterial entry into the animal through the punctures.
It is another object of the invention to provide a pellet implant system and method which would reduce the risk of infection in an animal caused by the procedure of administering a plurality of implants that include at least one pharmaceutical pellet implant and at least one non-pharmaceutical device implant in an animal or human without introducing additional antibiotic, bacteriostatic, or anti-inflammatory agents
into the body of the animal or human.
It is a further object of the invention to provide a pellet implant system and method which would reduce the labor required for administering a plurality of
implants that include at least one pharmaceutical pellet implant and at least one non- pharmaceutical device implant in an animal or human.
Other objects of the present invention will become immediately apparent to one skilled in the art upon reading the specification and claims.
These and other objects of the invention are met by providing a pellet implant system and method which permits implanting at least one pharmaceutical pellet
implant and at least one non pharmaceutical device implant in an animal in a single
injection.
In one aspect, the invention is directed to an implant containing one or more
pharmaceutical pellets and one or more non-pharmaceutical device pellets. In another aspect, the invention is directed to a pellet system and method of
implanting a plurality of implants that include at least one pharmaceutical pellet
implant and at least one non-pharmaceutical device implant in an animal or human in
a single combined procedure. The pellet system includes an implanter apparatus for
subcutaneously implanting pharmaceutical pellets or implantable non-pharmaceutical
devices in an animal or human through the bore of a hypodermic needle, and a plurality of pellets sized to be implanted through the needle. The pellets include at least one pharmaceutical first pellet and at least one non-pharmaceutical device
second pellet, which said pellets are simultaneous delivered as part of a single injection.
In one embodiment the non-pharmaceutical device pellet is an implantable identification device containing information for identifying the animal or human, or
source of the animal.
In another embodiment, the non-pharmaceutical device pellet is an implantable device containing information for purposes other than identifying the animal or human, or source of the animal.
In another embodiment the invention provides for a system and method of implanting in an animal or a human a plurality of implants that include at least one non-pharmaceutical device pellet by using an implanter apparatus equipped with a
hypodermic needle and an implant magazine remotely coupled to the needle. The
implants include at least one pharmaceutical agent pellet and at least one non-
pharmaceutical pellet which combined pellets are packaged in the magazine in
sequential order for sequential delivery of the pharmaceutical agent and the non-
pharmaceutical device. In a further embodiment, the pharmaceutical pellet contains antibiotics,
vaccines, growth promoters, growth stimulants, or anthelmintics, or mixtures thereof.
In still a further embodiment, the implants are implanted in animals selected
from cattle, sheep, goat, dog, swine, cat, fish, chickens, turkeys, and humans.
In still a further embodiment, the implants are implanted in animals selected from food animals, companion animals, zoo animals, and exotic animals.
DEFINITIONS AND CONVENTIONS The definitions and explanations below are for the terms as used throughout this entire document including both the specification and the claims. The term "pharmaceutical pellet," "pharmaceutical implant," or
"pharmaceutical pellet implant" as used herein refers to a physical device (1) that is used to deliver one or more pharmaceutical agents and (2) that is suitable for implantation under the skin of an animal or human.
The term "pharmaceutical agent" as used herein refers to a compound, substance, matter, or composition that is useful for effecting, and is intended to effect, some change in the subject to which it is administered. For example, "pharmaceutical agent" within the scope of this definition includes steroid hormones, prostaglandins, vitamins, antibiotics, antiinflammatory agents, chemotherapeutic agents, cardiovascular and antihypertensive agents. Term "pharmaceutical agent" also
includes microorganisms, either living, attenuated or dead, such as bacteria and
viruses.
The term "pharmaceutically acceptable" refers to those properties and/or
substances which are acceptable to the patient from a pharmacological/toxicological
point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient
acceptance and bioavailability.
The term "non-pharmaceutical implant," "non-pharmaceutical device
implant," or "non-pharmaceutical pellet implant" as used herein refers to any type of
physical device, other than pharmaceutical implant as defined above, that is suitable
for implantation under the skin of an animal or human. Example of suitable non- pharmaceutical implants for use with the invention include implantable identification devices for identifying individual subject or source of the subject carrying the implant,
or an implantable non-pharmaceutical devices that contains information for purposes other than identifying the animal or humans, such as information about the medical history and relevant commercial information.
The term "implanter" as used herein refers to a device or apparatus used to deliver or insert implants under the skin of an animal or human. Commonly, an
implanter has a hypodermic needle through the bore of which the implant is delivered. The term "hypodermic needle" associated with an implanter as used herein refers to a needle, cannula, tubing, or any other structure, flexible or rigid, that has a passageway for receiving and delivering the implant from the implanter into the animal. DETAILED DESCRIPTION OF THE INVENTION
All patent applications, patents, and literature references cited in this
specification are hereby incorporated by reference in their entirety. In the case of inconsistencies, the present description, including definitions, will control.
The present invention provides for a system and method of administering to an
animal or human at least one pharmaceutical implant containing one or more
pharmaceutical agents and at least one non-pharmaceutical implant in one combined
procedure. Broadly, the implantation system includes (a) an implanter apparatus having a hypodermic needle which is used to implant pharmaceutical agent pellets or
implantable microchips through the bore of the hypodermic needle, and (b) at least
one pharmaceutical pellet and at least one non-pharmaceutical device pellet. In use,
said pharmaceutical pellet and said non-pharmaceutical pellet are loaded into said
implanter apparatus and then delivered simultaneously or sequentially to the animal or
human in a single injection.
The invention may be practiced on human and any species of animals suitable for receiving implantable non-pharmaceutical implants or pharmaceutical implants, or
both as are known in the art. Suitable animals include, but are not limited to, companion animals, food animals, and other domestic animals, wildlife, and zoo animals. Specific examples of suitable animals include, but are not limited to, cattle, horses, goats, pigs, sheep, dog, cat, fish, and exotic species.
The invention may be practiced with any of those implantor apparatus commonly used in the art that are capable of implanting two or more implants in a single injection, such as those described in U.S. Patent No. 5,522,797, U.S. Patent 5,874,098, and U.S. Patent 4,105,030. The full disclosure of each of U.S. Patent No. 5,522,797, U.S. Patent 5,874,098, and U.S. Patent 4,105,030 is hereby incorporated
herein by reference.
An embodiment of this invention is described below. However, the invention
is expressly contemplated to encompass any type of implant system where both a non-
pharmaceutical pellet implant and a pharmaceutical pellet implant can be provided to an animal or human. This description is not to be taken in a limiting sense, but is
made merely for the purpose of describing the general principles of the invention. The
scope of the invention should be determined with reference to the claims. A suitable implanter apparatus is illustrated and described in detail in U.S.
Patent No. 4,105,030. Generally, the implant apparatus includes a handle, a finger
actuatable trigger attached to the handle, a needle, and a rod positioned within the
needle for pushing the pellets out of the needle. In use, the needle is loaded with a
preferred number of discrete pharmaceutical implants along with at least one non- pharmaceutical implant such as a microchip. An operator grasps the implanter and
urges the needle into the hide and under the skin of the target animal to make the implant receiving puncture. Once the needle containing the pellets has been inserted subcutaneously, the operator then depresses the trigger on the handle which causes the needle to be automatically withdrawn by a spring leaving the implanted pellets in
place.
Another suitable implanter apparatus is illustrated and described in detail in U.S. Patent 5,522,797, and generally includes a housing having a grip, a trigger attached to the grip, a needle, a pellet magazine strip, a pellet magazine, and an impeller. The pellets to be implanted are loaded into the magazine strip chamber. The needle is used to puncture through the skin or hide of an animal, and the trigger is squeezed to initiate injection of the pellets and so as to cause the impeller to be urged through the magazine chamber and needle bore, thereby forcing the pellets through the
bore of needle and into the puncture in the skin. Each magazine strip of the implanter typically contains multiple parallel aligned implants stored in corresponding pellet
chambers, which are connected by interconnecting webs. The chambers are arranged
in a side-by-side parallel relation. A plurality of strips can be connected in end-to-end
relation to increase the implanting capacity before the implanter requires reloading. In
use, each magazine chamber is loaded with a preferred number of discrete
pharmaceutical pellets along with at least one non-pharmaceutical pellet implant such as a microchip. Thereafter, the magazine is inserted into the implanter housing. An
operator grasps the implanter and urges the needle into the hide and under the skin of
the target animal to make the implant receiving puncture. The operator then depresses
the trigger member activating the propelling mechanism, forcing the implants through the needle bore and into the implant receiving puncture. The operator thereafter
withdraws the needle, leaving the implants in the animal.
The non-pharmaceutical pellet implant in the invention is expressly
contemplated to encompass any type of physical device, other than pharmaceutical pellet implants, that is suitable for implantation in the body of an animal or human and
that can be implanted using the method described therein. Example of suitable non- pharmaceutical pellet implants for use with the invention include, but are not limited to, implantable identification devices for identifying individual animals or humans, and implantable non-pharmaceutical devices that contain information for purposes other than identifying the animal or humans. One example of such implantable identification devices is an implantable electronic transponder or transmitter, commonly called a "microchip." The microchip contains an unique identification code and is implanted under the skin of a animal or human. These microchips are commercially available from several companies such as Destron Fearing, Trovan, and AVID. Another type of identification device suitable in the invention is illustrated and
described in detail in U.S. Patent 4,909,250, which is an implantable identification pellet imprinted with information for identification of an animal.
The implantable non-pharmaceutical, non-identification implant can be a
microchip that contains information about the medical history or relevant commercial information. Any suitable pharmaceutical pellet implant may be used with the present
invention. An example of such an implant is one containing one or more
pharmaceutical agents in the form of a pellet or a plurality of pellets. The use of the
pharmaceutical agent in either liquid or solid forms is specifically contemplated. In
the present invention, the nature or type of pharmaceutical agent contained in the
pharmaceutical implant is not critical and can be any substance such as enzymes or other organic catalysts, proteins and glycoproteins, peptides, antibodies, nucleic acids,
steroids, antibiotics, antimycotics, anti-narcotics, antihistamines, laxatives, vitamins, sedatives, anti-inflammatory substances, antimanics, stimulants, chemotherapeutic agents, contraceptives, radiopharmaceuticals, mineral and nutritional supplements, hormones, pharmaceuticals and other therapeutic agents. The pharmaceutical implants used in the present invention may also be employed for the delivery of microorganisms, either living, attenuated or dead such as bacteria, and viruses such as indigenous vira, enterovira, bacteriophages. The present invention is especially suited for the immediate and sustained delivery of hormones and steroids such as androgens, such as testosterone, trenbolone acetate (TBA), dihydroepiandroterone, and other
androgenic steroids, estrogens, such as estradiol-17-β, estradiol benzoate, zeralanone,
and other estrogenic steroids, progestins, such as progesterone, melengestrol acetate
(MGA), megestrol acetate, medroxyprogesterone acetate, norgestemet, norethidrone, and other progestin compounds, releasing factors, such as leutinizing hormone
releasing hormone and analogs, growth hormone releasing hormone and analogs,
thyroid releasing hormone and analogs, and other releasing factors and analogs, growth hormones/somatotropin, such as natural and recombinant somatotropins and
analogs from various species, growth factors, such as insulin-like growth factor, epidermal growth factor and other such factors. It is also especially suited for delivery
of anthelmintics, such as invermectins, and antigens.
Preferred pharmaceutical implants include implants containing pharmaceutical
agents for the suppression of estrus and inhibition of pregnancy such as estradiol benzoate. Another preferred pharmaceutical implant is one containing pharmaceutical
agents for promoting growth or enhancing body weight gain of animals such as MGA, a combination of MGA and TBA, or a combination of MGA, TBA and estradiol. A
number of implants for promoting growth or weight gain in animals are described, for example, in U.S. Patent Nos. 3, 417,182, 5,091,185, and 5,744,163. Other preferred pharmaceutical agents include antiobiotics such as beta-lactams and cephalosporins. Particulalry preferred is the use of ceftiofur in either its sodium salt, hydrochloride salt
or free acid form.
It is within the knowledge and skill of those skilled in the art to determine the amount of a pharmaceutical agent used in the implant. See, e.g., U.S. Patent 5,035,891. Generally, the amount of a pharmaceutical agent in the implant will vary depending on the identity of the compound; the size, age, weight, and species of the subject to be treated; the severity of the condition or the magnitude of the effect
desired, and so forth. These parameters are easily determined and factored by one of ordinary skill in the art. For example, a representative implant suitable for promoting
growth in steers contains a combination of about 200 mg of progesterone and about 20 mg of estradiol benzoate as the pharmaceutical agent. A representative implant
suitable for promoting growth in heifers contains a combination of about 200 mg of
testosterone propionate and about 20 mg estradiol benzoate as the pharmaceutical
agent. Any of a number of excipients may be employed in the pharmaceutical pellet
implant, including polyethylene glycol, magnesium stearate, cellulose and its
derivatives, especially ethylcellulose, lactose, polymeric supports and binders and coloring agents. The manufacture of a pharmaceutical pellet implant may be
accomplished through a variety of methods known in the art. For example, a process
for manufacturing pharmaceutical implants for the delivery of an effective amount of a bioactive peptide or peptide analog over a period of 1 to 12 months is illustrated and
described in detail in U.S. Patent 6,159,490, which includes steps of: grinding a copolymer of lactic acid and glycolic acid having a ratio of glycolide to lactide units of from about 0 to 5 : 1 to a particle size of between about 50 and 150 μm; wetting the ground and copolymer with an aqueous slurry of a bioactive peptide or peptide analog; blending the copolymer and the slurry to obtain a homogeneous mixture of the copolymer and between about 10 and 50% of the bioactive peptide; drying the mixture at reduced pressure and at a temperature not exceeding 25 degree C.; extruding the dried mixture at a temperature between about 70 and 110 degree C; and cutting cylindrical rods of about 1 to 2 mm diameter and between about 10 and 25 mm in length from the extruded mixture to form the implants.
The descriptions above should be interpreted in the illustrative and not the limited sense. While the invention has been disclosed in connection with the preferred
embodiment or embodiments thereof, it should be understood that there may be other embodiments which fall within the scope of the invention as defined by the following
claims.
Without further elaboration, it is believed that one skilled in the art can, using
the preceding description, practice the present invention to its fullest extent. The
following example is provided for purpose of illustrating the invention and is not intended to be limiting upon the scope of the claims. Those skilled in the art will
promptly recognize appropriate variations from the procedures both as to reactants
and as to reaction conditions and techniques.
EXAMPLE 1
Pharmaceutical Pellets Containing Melengestrol Acetate:
Pharmaceutical pellets containing melengestrol acetate are formulated by conventional tableting technology, such as wet granulation with water as a granulation liquid or dry granulation, followed by screening, sizing and tablet compression.
EXAMPLE 2
Implantation of an Identification Microchip and Melengestrol Acetate Pellets Five pharmaceutical pellets of Example 1 and one model TX1400L
identification microchip marketed by Electronic ID, Inc. are loaded into the magazine of an implanter apparatus having a hypodermic needle. The operator activates the implanter to first puncture the skin of an animal and then deliver the implant
composition through the needle and into the animal. In the case where the animal is a
heifer, it is preferred that the puncture occurs at the posterior portion of the ear. The
pharmaceutical pellets of the implant deliver the melengestrol acetate in an amount
and rate sufficient to promote growth, suppress estrus, and inhibit pregnancy, while
the microchip provides information identifying the animal when the microchip is
scanned with a HS59001-F Mini Portable Reader marketed by Electronic ID, Inc.

Claims (26)

CLAIM
1. A method for implanting at least one pharmaceutical pellet and at least one
non-pharmaceutical pellet under the skin of an animal or human in a single injection,
comprising the steps of:
a) providing an implanter apparatus for implanting pellets in an animal through the bore of a hypodermic needle;
b) loading said implanter apparatus with at least one pharmaceutical pellet and at least one non-pharmaceutical pellet; and c) inserting the hypodermic needle under the skin of the animal and injecting said pharmaceutical pellet and said non-pharmaceutical pellet under the skin of said
animal.
2. The method according to claim 1 wherein said implanter apparatus is equipped with an pellet magazine and wherein the said magazine is loaded with said
pharmaceutical pellet and said non-pharmaceutical pellet.
3. The method according to claim 1 including the steps of:
(a) inserting the hypodermic needle under the skin of the animal or human and
injecting said pharmaceutical pellet, and while
(b) maintaining the hypodermic needle in place under the skin of the animal or human,
sequentially injecting said non-pharmaceutical pellet.
4. The method according to claim 1 including the steps of:
(a) inserting the hypodermic needle under the skin of the animal or human and
injecting said non-pharmaceutical pellet, and while
(b) maintaining the hypodermic needle in place under the skin of the animal or human,
sequentially injecting said pharmaceutical pellet.
5. The method of according to claim 1 wherein said non-pharmaceutical pellet is
an identification device.
6. The method according to claim 5 wherein said identification device is a
microchip.
7. The method according to claim 5 wherein said identification device is a transponder or transmitter.
8. The method according to claim 1 wherein said pharmaceutical pellet contains
one or more pharmaceutical agents that comprise antibiotics, vaccines, growth promoters, growth stimulants, anthelmintics and mixtures thereof.
9. The method according to claim 8 wherein said pharmaceutical agent comprises
MGA, a combination of MGA and TBA, or a combination of MGA, TBA and
estradiol.
10. The method according to claim 1 including the step of providing a plurality of discrete pharmaceutical pellets.
11. The method according to claim 1 wherein said animal is selected from the group consisting of cattle, sheep, goat, dog, swine, cat, fish, chicken, and turkey.
12. The method according to claim 1 wherein said animal is selected from the
group consisting of food animals, companion animals, exotic animals, zoo animals,
and exotic animals.
13. An implant for subcutaneous implantation in an animal or human comprising:
(a) at least one non-pharmaceutical pellet; and
(b) at least one pharmaceutical pellet;
14. The implant according to claim 12 wherein said non-pharmaceutical pellet is an identification device.
15. The implant according to claim 13 wherein said identification device is
microchip.
16. The implant according to claim 13 wherein said identification device is a
transponder or transmitter.
17. The implant according to claim 13 wherein said pharmaceutical pellet contains
one or more pharmaceutical agents that comprise antibiotics, vaccines, growth promoters, growth stimulants, anthelmintics and mixtures thereof.
18. The method according to claim 17 wherein said pharmaceutical agent comprises MGA, a combination of MGA and TBA, or a combination of MGA, TBA
and estradiol.
19. The implant according to claim 13 wherein all said pellets are joined in a single unit.
20. A pellet implant system for implanting at least one pharmaceutical pellet and at least one non-pharmaceutical device pellet under the skin of an animal in one combined procedure, comprising
(a) an implanter apparatus for implanting pellets in an animal through the bore of a hypodermic needle; and
(b) at least one pharmaceutical pellet and at least one non-pharmaceutical device pellet, wherein all said pellets are loaded into said implanter apparatus for simultaneous delivery to the animal in a single injection.
21. The pellet implant system according to claim 18 wherein said implanter
apparatus is equipped with an pellet magazine and wherein the said magazine is
loaded with said pharmaceutical pellet and said non-pharmaceutical pellet.
22. The pellet implant system according to claim 18 wherein said non-
pharmaceutical pellet is an identification device.
23. The pellet implant system according to claim 18 wherein said identification
device is a microchip.
24. The pellet implant system according to claim 18 wherein said identification
device is a transponder or transmitter.
25. The pellet implant system according to claim 18 wherein said pharmaceutical
pellet contains one or more pharmaceutical agents that comprise antibiotics, vaccines, growth promoters, growth stimulants, anthelmintics and mixtures thereof.
26. The method according to claim 25 wherein said pharmaceutical agent comprises MGA, a combination of MGA and TBA, or a combination of MGA, TBA and estradiol.
AU2002324712A 2001-09-07 2002-09-04 A pellet implant system and method of administration Abandoned AU2002324712A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60/318,228 2001-09-07

Publications (1)

Publication Number Publication Date
AU2002324712A1 true AU2002324712A1 (en) 2003-03-24

Family

ID=

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11529310B2 (en) 2020-12-08 2022-12-20 Ruminant Biotech Corp Limited Devices and methods for delivery of substances to animals

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11529310B2 (en) 2020-12-08 2022-12-20 Ruminant Biotech Corp Limited Devices and methods for delivery of substances to animals

Similar Documents

Publication Publication Date Title
EP0969844B1 (en) Administration of an injectable antibiotic in the ear of an animal
Winzenburg et al. Biodegradable polymers and their potential use in parenteral veterinary drug delivery systems
US5874098A (en) Pellet implant system
EP1484033B1 (en) Liquid polymeric compositions for controlled release of bioactive substances
JP2003517014A (en) Pharmaceutical implant containing immediate release and sustained release components and administration method
Rothen-Weinhold et al. Formulation and technology aspects of conrolled drug delivery in animals
US6645192B2 (en) Pellet implant system for immediate and delayed release of antiparasitic drug
US20050118271A1 (en) Polytartrate composition
CN101001640A (en) Sustained release composition
US20030050595A1 (en) Pellet implant system and method of administration
Rathbone Delivering drugs to farmed animals using controlled release science and technology
JP2005522418A5 (en)
Cardinal et al. Drug delivery in veterinary medicine
Rathbone et al. Veterinary pharmaceutical dosage forms
Bloom Use of veterinary pharmaceuticals in the United States
AU2002324712A1 (en) A pellet implant system and method of administration
US20050169966A1 (en) Growth promoting pharmaceutical implant
US7767218B2 (en) Pain relief implant pellet and method using same
AU775037B2 (en) Pellet implant system
Treves-Brown et al. Methods of drug administration
CA2417843C (en) Administration of an injectable antibiotic in the ear of an animal
Janzen The Clinical Management of Respiratory Disease in Cow-Calf Operations
JPS63248353A (en) Estriol growth promoter
WO2002026179A1 (en) Pain relief implant pellet and method using same